A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)

Exclusion Criteria

• •History of invasive pneumococcal disease
• •Known hypersensitivity to any component of pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine.
• •Known or suspected impairment of immune function
• •Coagulation disorder contraindicating intramuscular vaccination
• •History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
• •Female participant: positive urine or serum pregnancy test
• •Prior administration of any pneumococcal vaccine
• •Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention at least 30 days before study entry.
• •Received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination. (Note: Topical, ophthalmic, intra-articular or soft-tissue \[e.g., bursa, tendon steroid injections\], and inhaled/nebulized steroids are permitted).
• •Received immunosuppressive therapy
• •Received a blood transfusion or blood products within 6 months of enrollment
• •Participated in another clinical study of an investigational product within 2 months of enrollment
• •Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence.